LPAA
Launch One Acquisition Corp
$
10.510
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
10.520
Open
10.520
VWAP
10.52
Vol
2.04K
Mkt Cap
302.16M
Low
10.510
Amount
21.50K
EV/EBITDA(TTM)
--
Total Shares
28.75M
EV
302.47M
EV/OCF(TTM)
--
P/S(TTM)
--
Launch One Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It has not selected any business combination target and the Company has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target. It has no operations nor generated any revenues.
Show More
Valuation Metrics
The current forward P/E ratio for Launch One Acquisition Corp (LPAA.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Launch One Acquisition Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.60
Current PS
10.53
Overvalued PS
3.03
Undervalued PS
-1.84
Financials
Annual
Quarterly
FY2025Q2
YoY :
+2772.88%
-637.84K
Operating Profit
FY2025Q2
YoY :
-8756.96%
1.92M
Net Income after Tax
FY2025Q2
0.07
EPS - Diluted
FY2025Q2
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
LPAA News & Events
Events Timeline
2025-10-15 (ET)
2025-10-15
07:33:36
Minovia Granted Orphan Drug Designation for MNV-201 in Myelodysplastic Syndromes (MDS)
2025-09-18 (ET)
2025-09-18
07:32:34
Minovia Granted Fast Track Designation for MNV-201 in MDS
2025-08-27 (ET)
2025-08-27
07:19:45
Minovia Receives $350,000 Grant from Countdown for a Cure Foundation
Sign Up For More Events
Sign Up For More Events
News
9.0
09-17GlobenewswireMinovia Therapeutics Obtains FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
9.0
09-17GlobenewswireMinovia Therapeutics Granted FDA Fast Track Status for MNV-201 in Treating Myelodysplastic Syndrome
8.5
08-27Yahoo FinanceMinovia Therapeutics Receives $350,000 Grant from Countdown for a Cure Foundation to Advance Mitochondrial Blood Biomarker Development
Sign Up For More News
People Also Watch
DSGN
Design Therapeutics Inc
6.870
USD
+4.89%
AVIR
Atea Pharmaceuticals Inc
3.250
USD
+0.31%
ALDX
Aldeyra Therapeutics Inc
4.810
USD
-2.43%
ELMD
Electromed Inc
24.340
USD
-3.64%
LANV
Lanvin Group Holdings Ltd
2.090
USD
0.00%
HOND
HCM II Acquisition Corp
18.600
USD
+0.86%
SMTI
Sanara Medtech Inc
27.870
USD
+0.98%
PBFS
Pioneer Bancorp Inc
13.150
USD
-1.87%
FORR
Forrester Research Inc
7.520
USD
-3.71%
CDRO
Codere Online Luxembourg SA
5.690
USD
-4.37%
FAQ
What is Launch One Acquisition Corp (LPAA) stock price today?
The current price of LPAA is 10.51 USD — it has decreased -0.19 % in the last trading day.
What is Launch One Acquisition Corp (LPAA)'s business?
What is the price predicton of LPAA Stock?
What is Launch One Acquisition Corp (LPAA)'s revenue for the last quarter?
What is Launch One Acquisition Corp (LPAA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Launch One Acquisition Corp (LPAA)'s fundamentals?
How many employees does Launch One Acquisition Corp (LPAA). have?